DK3105253T3 - Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse - Google Patents

Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3105253T3
DK3105253T3 DK15706124.3T DK15706124T DK3105253T3 DK 3105253 T3 DK3105253 T3 DK 3105253T3 DK 15706124 T DK15706124 T DK 15706124T DK 3105253 T3 DK3105253 T3 DK 3105253T3
Authority
DK
Denmark
Prior art keywords
seq
amino acid
antibody
acid sequence
gly
Prior art date
Application number
DK15706124.3T
Other languages
English (en)
Inventor
Yvonne Chinn
Julie Q Hang
Christian W Siebel
Yan Wu
Daniel Lafkas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52574459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3105253(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3105253T3 publication Critical patent/DK3105253T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (31)

1. Isoleret antistof, der binder sig til humant Jaggedl, hvor antistoffet omfatter en HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 35 eller 78, en HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 28 eller 36, en HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 55 eller 59, hvor X er en hvilken som helst anden aminosyre end S eller H, en HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, en HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og en HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16 eller 40.
2. Isoleret antistof ifølge krav 1, hvor antistoffet omfatter: a) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 55, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 40; eller b) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 59, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16; eller c) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 28, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 59, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16.
3. Isoleret antistof ifølge et hvilket som helst af de foregående krav, hvor antistoffet omfatter: a) en VH-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 54, og en VL-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 34; eller b) en VH-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 58, og en VL-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 10; eller c) en VH-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 62, og en VL-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 26; eller d) en VH-sekvens ifølge SEQ ID NO: 54 og en VL-sekvens ifølge SEQ ID NO: 34; eller e) en VH-sekvens ifølge SEQ ID NO: 58 og en VL-sekvens ifølge SEQ ID NO: 10; eller f) en VH-sekvens ifølge SEQ ID NO: 62 og en VL-sekvens ifølge SEQ ID NO: 26.
4. Isoleret antistof ifølge krav 3, hvor antistoffet omfatter en VH-sekvens ifølge SEQ ID NO: 54 og en VL-sekvens ifølge SEQ ID NO: 34.
5. Isoleret antistof ifølge krav 4, hvor tungkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 56 eller SEQ ID NO: 57, og letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 53.
6. Isoleret antistof ifølge et hvilket som helst af de foregående krav, hvor X er valgt blandt A, D, E, G, I, K, L, N, Q, R, T og V.
7. Isoleret antistof ifølge et hvilket som helst af de foregående krav, hvor X er T.
8. Isoleret antistof ifølge et hvilket som helst af de foregående krav, omfattende: a) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 37, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 40; eller b) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 64, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16; eller c) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 28, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 64, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16; eller d) en VH-sekvens ifølge SEQ ID NO: 33 og en VL-sekvens ifølge SEQ ID NO: 34; eller e) en VH-sekvens ifølge SEQ ID NO: 65 og en VL-sekvens ifølge SEQ ID NO: 10; eller f) en VH-sekvens ifølge SEQ ID NO: 66 og en VL-sekvens ifølge SEQ ID NO: 26.
9. Isoleret antistof ifølge krav 8, hvor antistoffet omfatter en VH-sekvens ifølge SEQ ID NO: 33 og en VL-sekvens ifølge SEQ ID NO: 34.
10. Antistof ifølge et hvilket som helst af de foregående krav, der er et IgGl-antistof i fuld længde.
11. Antistof ifølge krav 10, hvor antistoffet i det væsentlige mangler en effektorfunktion.
12. Antistof ifølge krav 10 hvor tungkæden omfatter en N297G- eller N297A-mutation.
13. Isoleret antistof ifølge krav 8, hvor tungkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 51, og letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 53.
14. Isoleret antistof ifølge krav 8, hvor tungkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 52, og letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 53.
15. Antistof ifølge krav 8, hvor antistoffet omfatter: a) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 69 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 75; eller b) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 70 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 76; eller c) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 79 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 75; eller d) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 80 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 76.
16. Antistof ifølge et hvilket som helst af de foregående krav, hvor antistoffet er en antagonist for Jaggedl-medieret signalering.
17. Antistof ifølge et hvilket som helst af de foregående krav, hvor antistoffet ikke binder sig til humant Jagged2, og/eller hvor antistoffet ikke binder sig til humant DLL4, og/eller hvor antistoffet ikke binder sig til humant DLL1, og/eller hvor antistoffet ikke binder sig til murint Jagged2, murint DLL4 og/eller murint DLL1.
18. Isoleret nukleinsyre, der koder for antistoffet ifølge et hvilket som helst af de foregående krav.
19. Værtscelle, der omfatter den isolerede nukleinsyre ifølge krav 18.
20. Fremgangsmåde til fremstilling af et antistof, der omfatter dyrkning af værtscellen ifølge krav 19, således at antistoffet fremstilles.
21. Immunkonjugat, der omfatter antistoffet ifølge et hvilket som helst af kravene 1 til 17 og et cytotoksisk middel.
22. Farmaceutisk formulering, der omfattende antistoffet ifølge et hvilket som helst af kravene 1 til 17 og en farmaceutisk acceptabel bærer.
23. Antistof ifølge et hvilket som helst af kravene 1 til 17 eller immunkonjugat ifølge krav 21 til anvendelse som medikament.
24. Antistof ifølge et hvilket som helst af kravene 1 til 17 eller immunkonjugat ifølge krav 21 til anvendelse ved behandling afkræft.
25. Antistof ifølge et hvilket som helst af kravene 1 til 17 til anvendelse ved behandling af allergi, astma, autoimmun sygdom, sygdomme forbundet med bægercellemetaplasi (for eksempel i lungerne) og/eller overskydende slim.
26. Antistof til anvendelse ifølge krav 25 til anvendelse ved behandling en sygdom forbundet med bægercellemetaplasi.
27. Antistof til anvendelse ifølge krav 26 til anvendelse ved behandling af astma, cystisk fibrose, kronisk obstruktiv lungesygdom eller Barretts øsofagus.
28. Antistof til anvendelse ifølge krav 24, hvor kræften er udvalgt blandt brystkræft, lungekræft, hjernekræft, livmoderhalskræft, tyktarmskræft, leverkræft, galdegangskræft, bugspytkirtelkræft, hudkræft samt B-celle- og T-celle-maligniteter.
29. Isoleret antistof ifølge et hvilket som helst af kravene 1 til 17 konjugeret til en markør.
30. Isoleret antistof ifølge krav 29, hvor markøren er en positronemitter, fortrinsvis hvor positronemitteren er 89Zr.
31. Fremgangsmåde til påvisning af humant Jaggedl i en biologisk prøve, der omfatter at bringe den biologiske prøve i kontakt med antistoffet ifølge et hvilket som helst af kravene 1 til 17, 29 og 30 under betingelser, der tillader binding af antistoffet til et naturligt forekommende humant Jaggedl, og at påvise om et kompleks dannes mellem antistoffet og et naturligt forekommende humant Jaggedl i den biologiske prøve.
DK15706124.3T 2014-02-12 2015-02-11 Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse DK3105253T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939110P 2014-02-12 2014-02-12
PCT/US2015/015456 WO2015123325A1 (en) 2014-02-12 2015-02-11 Anti-jagged1 antibodies and methods of use

Publications (1)

Publication Number Publication Date
DK3105253T3 true DK3105253T3 (da) 2018-09-03

Family

ID=52574459

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15706124.3T DK3105253T3 (da) 2014-02-12 2015-02-11 Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse

Country Status (33)

Country Link
US (5) US9518121B2 (da)
EP (3) EP3105253B1 (da)
JP (1) JP6571115B2 (da)
KR (2) KR102030891B1 (da)
CN (2) CN111499741A (da)
AR (1) AR099465A1 (da)
AU (3) AU2015217271B2 (da)
BR (1) BR112016017986A2 (da)
CA (2) CA3045124A1 (da)
CL (1) CL2016002004A1 (da)
CR (1) CR20160362A (da)
DK (1) DK3105253T3 (da)
EA (1) EA201691610A8 (da)
ES (1) ES2685424T3 (da)
HR (1) HRP20181359T1 (da)
HU (1) HUE039940T2 (da)
IL (1) IL246736B (da)
LT (1) LT3105253T (da)
MA (1) MA39248B1 (da)
MX (1) MX372675B (da)
MY (1) MY176855A (da)
PE (1) PE20161335A1 (da)
PH (2) PH12016501435A1 (da)
PL (1) PL3105253T3 (da)
PT (1) PT3105253T (da)
RS (1) RS57608B1 (da)
SG (2) SG10201808259TA (da)
SI (1) SI3105253T1 (da)
TR (1) TR201810635T4 (da)
TW (2) TW201902515A (da)
UA (1) UA121464C2 (da)
WO (1) WO2015123325A1 (da)
ZA (1) ZA201800315B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
KR20200143502A (ko) 2012-08-13 2020-12-23 제넨테크, 인크. 항-jagged 항체 및 사용 방법
AU2014236815B2 (en) 2013-03-15 2019-04-04 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3105253B1 (en) 2014-02-12 2018-06-27 F. Hoffmann-La Roche AG Anti-jagged1 antibodies and methods of use
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
DK3183337T3 (da) * 2014-08-22 2019-04-01 Procella Therapeutics Ab Anvendelse af Jagged 1/Frizzled 4 som celleoverflademarkør til isolering af humane kardiale ventrikulære progenitorceller
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017172086A1 (en) 2016-02-19 2017-10-05 Leung Chuen Yan Genetic markers for engraftment of human cardiac ventricular progenitor cells
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
AU2018318231A1 (en) 2017-08-18 2020-02-13 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019038587A1 (en) 2017-08-23 2019-02-28 Procella Therapeutics Ab USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS
US12110342B2 (en) 2018-01-31 2024-10-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
JP2006510586A (ja) 2002-08-29 2006-03-30 ユニバーシティー オブ サザンプトン 肝疾患治療のための薬剤の調製におけるアポトーシス誘導物質の使用方法
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
CA2546017A1 (en) 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006071441A2 (en) * 2004-11-30 2006-07-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007058987A1 (en) * 2005-11-10 2007-05-24 Bristol-Myers Squibb Company Methods of identifying compounds that inhibit notch cleavage
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1973950B1 (en) * 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4 antibodies and methods using the same
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20080226645A1 (en) * 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
EP2155249A4 (en) * 2007-05-15 2011-11-16 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
CA2729602A1 (en) 2008-07-08 2010-01-14 Oncomed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
AR073717A1 (es) 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
PH12012500574A1 (en) * 2009-09-30 2012-10-22 Genentech Inc Notch1-antagonist-resistant cancer(s) using notch3 antagonists
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
WO2012106529A1 (en) 2011-02-02 2012-08-09 The Trustees Of Princeton University Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
SG11201408554QA (en) * 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
KR20200143502A (ko) 2012-08-13 2020-12-23 제넨테크, 인크. 항-jagged 항체 및 사용 방법
GB201300706D0 (en) * 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
AU2014236815B2 (en) 2013-03-15 2019-04-04 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
EP3105253B1 (en) 2014-02-12 2018-06-27 F. Hoffmann-La Roche AG Anti-jagged1 antibodies and methods of use
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Also Published As

Publication number Publication date
JP2017512067A (ja) 2017-05-18
AR099465A1 (es) 2016-07-27
PL3105253T3 (pl) 2018-12-31
EP3105253A1 (en) 2016-12-21
US20170137531A1 (en) 2017-05-18
LT3105253T (lt) 2018-09-10
PT3105253T (pt) 2018-10-04
MY176855A (en) 2020-08-24
BR112016017986A2 (pt) 2017-10-10
CN106068277A (zh) 2016-11-02
MX2016010433A (es) 2016-09-22
EA201691610A8 (ru) 2018-05-31
CA2936565C (en) 2020-08-11
CL2016002004A1 (es) 2017-01-20
US20240384000A1 (en) 2024-11-21
TW201902515A (zh) 2019-01-16
PH12016501435A1 (en) 2017-02-06
US9518121B2 (en) 2016-12-13
US11926674B2 (en) 2024-03-12
US20180371098A1 (en) 2018-12-27
HUE039940T2 (hu) 2019-02-28
AU2018229549A1 (en) 2018-10-04
EP3105253B1 (en) 2018-06-27
CA3045124A1 (en) 2015-08-20
AU2015217271B2 (en) 2018-10-25
RS57608B1 (sr) 2018-11-30
US20210206871A1 (en) 2021-07-08
SI3105253T1 (sl) 2018-10-30
HRP20181359T1 (hr) 2018-10-19
MX372675B (es) 2020-03-25
MA39248B1 (fr) 2018-10-31
ZA201800315B (en) 2020-05-27
EP3428190A1 (en) 2019-01-16
SG11201606607UA (en) 2016-09-29
US10858440B2 (en) 2020-12-08
SG10201808259TA (en) 2018-10-30
AU2020203547A1 (en) 2020-06-18
CN106068277B (zh) 2021-08-24
AU2015217271A1 (en) 2016-08-11
CR20160362A (es) 2016-09-20
EA201691610A1 (ru) 2016-11-30
ES2685424T3 (es) 2018-10-09
WO2015123325A1 (en) 2015-08-20
TR201810635T4 (tr) 2018-08-27
KR102030891B1 (ko) 2019-10-11
IL246736A0 (en) 2016-08-31
PE20161335A1 (es) 2016-12-07
JP6571115B2 (ja) 2019-09-04
KR20160118348A (ko) 2016-10-11
TWI631135B (zh) 2018-08-01
KR20190114046A (ko) 2019-10-08
CA2936565A1 (en) 2015-08-20
EP3825332A1 (en) 2021-05-26
IL246736B (en) 2020-09-30
US20150252117A1 (en) 2015-09-10
UA121464C2 (uk) 2020-06-10
TW201613963A (en) 2016-04-16
US10011661B2 (en) 2018-07-03
CN111499741A (zh) 2020-08-07
PH12020550781A1 (en) 2021-08-02

Similar Documents

Publication Publication Date Title
US20240384000A1 (en) Anti-Jagged1 Antibodies and Methods of Use
US20240034805A1 (en) Anti-Jagged Antibodies and Methods of Use
US20140248286A1 (en) Anti-hemagglutinin antibodies and methods of use
HK1227041B (zh) 抗锯齿蛋白1抗体及使用方法
HK1227041A1 (en) Anti-jagged1 antibodies and methods of use
HK1209432B (zh) 抗锯齿蛋白抗体及使用方法